Approval · Notice of Compliance 8969 · 2007
ZOMIG: Notice of Compliance 8969
Issued August 10, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8969
- Date
- August 10, 2007
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the clinical trials and adverse reactions sections and other revisions to the product monograph
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOMIG | Not yet assigned | — |
| ZOMIG RAPIMELT | Not yet assigned | — |
| ZOMIG NASAL SPRAY | Not yet assigned | — |
Medicinal ingredients
- ZOLMITRIPTAN 2.5 MG per TAB
- ZOLMITRIPTAN 2.5 MG per 100MCL
- ZOLMITRIPTAN 5 MG per 100MCL